Anja Göder

Dr. Anja Göder

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAnja Göder
Anja Göder
CEClaudia Emmerich
Claudia Emmerich
TNTeodora Nikolova
Teodora Nikolova
NKNicole Kiweler
Nicole Kiweler
MSMaria Schreiber
Maria Schreiber
Oliver KrämerOliver Krämer
Oliver Krämer
Checkpoint kinases sense replicative stress to prevent DNA damage. Here we show that the histone deacetylases HDAC1/HDAC2 sustain the phosphorylation of the checkpoint kinases ATM, CHK1 and CHK2, activity of the cell cycle gatekeeper kinases WEE1 and CDK1, and induction of the tumour suppressor p53 in response to stalled DNA replication. Consequently, HDAC inhibition upon replicative stress promotes mitotic catastrophe. Mechanistically, HDAC1 and HDAC2 suppress the expression of PPP2R3A/PR130, a regulatory subunit of the trimeric serine/threonine phosphatase 2 (PP2A). Genetic elimination of PR130 reveals that PR130 promotes dephosphorylation of ATM by PP2A. Moreover, the ablation of PR130 slows G1/S phase transition and increases the levels of phosphorylated CHK1, replication protein A foci and DNA damage upon replicative stress. Accordingly, stressed PR130 null cells are very susceptible to HDAC inhibition, which abrogates the S phase checkpoint, induces apoptosis and reduces the homologous recombination protein RAD51. Thus, PR130 controls cell fate decisions upon replicative stress.

1 January 2017 in Cellular Signalling
Verified
Journal Article
Closed access
CSClaudia Schäfer
Claudia Schäfer
AGAnja Göder
Anja Göder
MBMandy Beyer
Mandy Beyer
NKNicole Kiweler
Nicole Kiweler
NMNisintha Mahendrarajah
Nisintha Mahendrarajah
Oliver KrämerOliver Krämer
Oliver Krämer

21 May 2015 in Carcinogenesis
Verified
Journal Article
Closed access
PDF file
AGAnja Göder
Anja Göder
GNGeorg Nagel
Georg Nagel
AKAlexander Kraus
Alexander Kraus
BDBastian Dörsam
Bastian Dörsam
NSNina Seiwert
Nina Seiwert
JFJörg Fahrer
Jörg Fahrer
Alkylating agents are present in food and tobacco smoke, but are also used in cancer chemotherapy, inducing the DNA lesion O6-methylguanine (O6-MeG). This critical adduct is repaired by O6-methylguanine-DNA methyltransferase (MGMT), resulting in MGMT inactivation and degradation. In the present study, we analyzed the effects of the natural disulfide compound lipoic acid (LA) on MGMT in vitro and in colorectal cancer (CRC) cells. We show that LA, but not its reduced form DHLA potently inhibits the activity of recombinant MGMT by interfering with its catalytic Cys-145 residue, which was partially reversible by N-acetyl cysteine. Incubation of HCT116 CRC cells with LA altered their GSH pool and caused a decline in MGMT activity. This was mirrored by LA-induced depletion of MGMT protein, which was not attributable to changes in MGMT mRNA levels. Loss of MGMT protein coincided with LA-induced autophagy, a process resulting in lysosomal degradation of proteins, including presumably MGMT. LA stimulated autophagy in a p53-independent manner as revealed by the response of isogenic HCT116 cell lines. Knockdown of the crucial autophagy component beclin-1 and chemical inhibitors blocked LA-induced autophagy, but did not abrogate LA-triggered MGMT degradation. Concomitant with MGMT depletion, LA pre-treatment resulted in enhanced O6-MeG levels in DNA. It also increased the cytotoxicity of the alkylating anticancer drug temozolomide (TMZ) in TMZ-resistant CRC cells. Taken together, our study showed that the natural compound LA inhibits MGMT and induces autophagy. Furthermore, LA enhanced the cytotoxic effects of TMZ, which makes it a candidate for a supplement in cancer therapy.

20 December 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
BDBastian Dörsam
Bastian Dörsam
AGAnja Göder
Anja Göder
NSNina Seiwert
Nina Seiwert
BKBernd Kaina
Bernd Kaina
JFJörg Fahrer
Jörg Fahrer

4 June 2020 in EMBO Reports
Verified
Journal Article
Open access
PDF file
MRMichael D Rainey
Michael D Rainey
AQAisling Quinlan
Aisling Quinlan
CCChiara Cazzaniga
Chiara Cazzaniga
SMSofija Mijic
Sofija Mijic
OMOliviano Martella
Oliviano Martella
CSCorrado Santocanale
Corrado Santocanale
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

30 July 2019 in Cells
Verified
Journal Article
Open access
PDF file
CNCarina Neitzel
Carina Neitzel
NSNina Seiwert
Nina Seiwert
AGAnja Göder
Anja Göder
EDErika Diehl
Erika Diehl
CWCarina Weber
Carina Weber
JFJörg Fahrer
Jörg Fahrer
Lipoic acid (LA) is a redox-active disulphide compound, which functions as a pivotal co-factor for mitochondrial oxidative decarboxylation. LA and chemical derivatives were shown to target mitochondria in cancer cells with altered energy metabolism, thereby inducing cell death. In this study, the impact of LA on the tumor suppressor protein p53 was analyzed in various colorectal cancer (CRC) cell lines, with a focus on the mechanisms driving p53 degradation. First, LA was demonstrated to trigger the depletion of both wildtype and mutant p53 protein in all CRC cells tested without influencing its gene expression and preceded LA-triggered cytotoxicity. Depletion of p53 coincided with a moderate, LA-dependent ROS production, but was not rescued by antioxidant treatment. LA induced the autophagy receptor p62 and differentially modulated autophagosome formation in CRC cells. However, p53 degradation was not mediated via autophagy as shown by chemical inhibition and genetic abrogation of autophagy. LA treatment also stabilized and activated the transcription factor Nrf2 in CRC cells, which was however dispensable for p53 degradation. Mechanistically, p53 was found to be readily ubiquitinylated and degraded by the proteasomal machinery following LA treatment, which did not involve the E3 ubiquitin ligase MDM2. Intriguingly, the combination of LA and anticancer drugs (doxorubicin, 5-fluorouracil) attenuated p53-mediated stabilization of p21 and resulted in synergistic killing in CRC cells in a p53-dependant manner.